Prosecution Insights
Last updated: April 19, 2026

Grimes & Yvon LLP

23 pending office actions • 18 clients

Portfolio Summary

23
Total Pending OAs
7
Final Rejections
16
Non-Final OAs

Client Portfolio (18 clients)

Client (Assignee)Pending OAs
Memorial Sloan Kettering Cancer Center 2
Angiocrine Bioscience, Inc. 2
Oxford Biomedica (Us) LLC 2
Janssen Pharmaceutica NV 2
Fempharma, LLC 1
Tri-Institutional Therapeutics Discovery Institute, Inc. 1
Georgetown University 1
Cornell University 1
USWM CT,LLC 1
Gomboc, LLC 1
Angiocrine Bioscience, Inc. 1
Sapience Therapeutics, Inc. 1
UCL Business Ltd 1
Oxford Biomedica (Uk) Limited 1
Nunona Inc. 1
Shuttle Pharmaceuticals Holdings, Inc. 1
Klinikum Der Universitat Munchen 1
Memorial Sloan Kettering Cancer Center 1

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
18622971 Pharmaceutical Composition and Method for Treating or Preventing Candidiasis Fempharma, LLC YU, HONG 1614 Non-Final OA Mar 31, 2024
18287848 CEMENTITIOUS AND WATER-BASED EPOXY 3D PRINTING MORTAR AND METHODS FOR MAKING THE SAME Unknown WEISS, PAMELA HL 1732 Non-Final OA Oct 20, 2023
18555079 ENGINEERED HLA MOLECULES USEFUL FOR T CELL AND NK CELL ACTIVATION AND EXPANSION Memorial Sloan Kettering Cancer Center STAVROU, CONSTANTINA E 1632 Non-Final OA Oct 12, 2023
18267992 CD40 BINDING MOLECULES AND USES THEREOF Tri-Institutional Therapeutics Discovery Institute, Inc. HADDAD, MAHER M 1641 Non-Final OA Jun 30, 2023
18138058 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION Georgetown University BARSKY, JARED 1628 Non-Final OA Apr 22, 2023
18033249 CD4+ TFH-LIKE CELLS AS A THERAPEUTIC TARGET Cornell University BENAVIDES, JENNIFER ANN 1675 Non-Final OA Apr 21, 2023
18249248 INDUCTION OF FERROPTOSIS FOR CANCER THERAPY Memorial Sloan Kettering Cancer Center HUDSON, AMY ROSE 1636 Non-Final OA Apr 15, 2023
18041080 CRYOPRESERVED ENDOTHELIAL CELL COMPOSITIONS Angiocrine Bioscience, Inc. ABBOTT, KODYE LEE 1634 Non-Final OA Feb 09, 2023
17924982 METHOD OF TREATMENT OF CANCER OR TUMOUR USWM CT,LLC AEDER, SEAN E 1642 Non-Final OA Jan 23, 2023
18099486 MAGNETIC INTERVERTEBRAL DISC REPLACEMENT DEVICES AND METHODS THEREOF Gomboc, LLC RAMANA, ANURADHA 3775 Final Rejection Jan 20, 2023
18003124 ENDOTHELIAL CELLS FOR MITIGATION OF CHEMOTHERAPY-INDUCED TOXICITY Angiocrine Bioscience, Inc. SCHUBERG, LAURA J 1631 Non-Final OA Dec 22, 2022
18011171 Administration of CEBP-Beta Antagonist and Methods of Use Sapience Therapeutics, Inc. STEELE, AMBER D 1658 Non-Final OA Dec 17, 2022
18009320 CHIMERIC ANTIGEN RECEPTOR CELL UCL Business Ltd HILL, KEVIN KAI 1638 Final Rejection Dec 08, 2022
18050834 METHODS AND COMPOSITIONS FOR THE PURIFICATION OF ADENO-ASSOCIATED VIRUS Oxford Biomedica (Us) LLC BURKHART, MICHAEL D 1638 Non-Final OA Oct 28, 2022
17909427 Replication Competent Virus Assay Oxford Biomedica (Uk) Limited WANG, RUIXUE 1672 Final Rejection Sep 05, 2022
17821884 ADENO-ASSOCIATED VIRUS FORMULATIONS Oxford Biomedica (Us) LLC GILL, RACHEL B 1671 Final Rejection Aug 24, 2022
17724493 PLANT-BASED BABY FOOD COMPOSITIONS Nunona Inc. NGUYEN, THANH H 1792 Non-Final OA Apr 20, 2022
17614521 COMPOSITIONS AND METHODS FOR THYMIC REGENERATION AND T-CELL RECONSTITUTION Angiocrine Bioscience, Inc. JOHNSON, ALLISON MARIE 1638 Final Rejection Nov 27, 2021
17509910 Methods of Safe Administration of Anti-Tau Antibody Janssen Pharmaceutica NV FONTAINHAS, AURORA M 1675 Final Rejection Oct 25, 2021
17509889 Methods of Reducing Tau in Human Subjects Janssen Pharmaceutica NV WANG, CHANG YU 1675 Non-Final OA Oct 25, 2021
17476148 PREDICTIVE BIOMARKERS FOR ADVERSE EFFECTS OF RADIATION THERAPY Shuttle Pharmaceuticals Holdings, Inc. LIMBAUGH, KATHRYN ELIZABETH 1797 Final Rejection Sep 15, 2021
17435634 CCR8 EXPRESSING LYMPHOCYTES FOR TARGETED TUMOR THERAPY Klinikum Der Universitat Munchen WESTON, ALYSSA G 1633 Non-Final OA Sep 01, 2021
17196631 METHODS AND COMPOSITIONS FOR DETECTION OF HPV DNA AND DIAGNOSIS AND MONITORING OF HPV-ASSOCIATED CANCERS Memorial Sloan Kettering Cancer Center HANEY, AMANDA MARIE 1682 Non-Final OA Mar 09, 2021

Managing Grimes & Yvon LLP's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month